Clinical outcomes of RCTs of CVAD thromboprophylaxis
| Reference . | Intervention . | Thrombosis, n/N (%) . | P . | Symptomatic thrombosis, n/N (%) . | P . | Major bleeding, n/N (%) . | P . | Clinically relevant nonmajor bleeding, n/N (%) . | P . | |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 | Control | 15/40 (37.5) | P < .001 | 13/40 (32.5) | NR | |||||
| Warfarin, 1 mg/d | 4/42 (9.5) | 4/42 (9.5) | ||||||||
| 31 | Control | 8/13 (62) | P = .002 | NR | NR | 0/13 | NR | |||
| Dalteparin, 2500 U/d | 1/16 (6) | 1/16 (6) | ||||||||
| 32 | Control | 15/115 (13) | P = .03 | 0/115 | NR | |||||
| Warfarin, 1 mg/d | 5/108 (5) | 0/108 | ||||||||
| 33 | Control | 3/29 (10.3) | NR | 0/29 | NR | |||||
| Warfarin, 1 mg/d | 7/55 (12.8) | 3/55 (5.5) | ||||||||
| 34 | Control | 5/43 (11.6) | P = .42 | 0/43 | NR | |||||
| Warfarin, 1 mg/d | 8/45 (17.8) | 1/45 (2.2) | ||||||||
| 35 | Warfarin, 1 mg/d | 4/24 (16.7) | P = .48 | 2/24 (8.3) | NR | 0/24 | NR | |||
| Nadroparin, 2850 U/d | 6/21 (23.8) | 1/21 (4.8) | 1/21 (4.8) | |||||||
| 36 | Enoxaparin, 40 mg/d | 22/155 (12.9) | RR: 0.78 (95% CI: 0.47-1.31; P = .35) | 2/155 (1.3) | RR: 0.32 (95% CI: 0.07-1.66) | 0/155 | NR | |||
| Placebo | 28/155 (14.2) | 6/155 (3.9) | 0/155 | |||||||
| 37 | Warfarin, 1 mg/d | 6/130 (4.6) | HR: 1.20; (95% CI: 0.37-3.94) | 0/130 | P = .07 | |||||
| Placebo | 5/125 (4) | 3/125 (2.4) | ||||||||
| 38 | Dalteparin, 5000 U/d | 21/294 (7.1) | NR | 11/294 (3.7) | OR: 1.09 (95% CI: 0.37-3.19) P = .88 | 1/294 (0.3) | NR | |||
| Placebo | 11/145 (7.6) | 5/145 (3.4) | 1/145 (0.7) | |||||||
| 39 | Nadroparin, 2850 U | 7/41 (17) | P = .49 | 0/41 | NR | 0/56 | NR | 2/56 (4) | NR | |
| Placebo | 4/46 (9) | 1/46 (2.2) | 0/57 | 2/57 (4) | ||||||
| 40 | Warfarin, 1 mg/d | 24/408 (5.9) | RR: 0.99 (95% CI: 0.57-1.72), P = .98 | 7/408 (1.7) | RR: 6.93 (95% CI: 0.86-56.08), P = .07 | |||||
| No warfarin | 24/404 (5.9) | 1/404 (0.25) | ||||||||
| Warfarin (INR 1.5-2.0) | 13/473 (2.7) | RR: 0.38 (95% CI: 0.20-0.71), P = .002 | 16/473 (3.4) | RR: 2.28 (95% CI: 0.95-5.48), P = .09 | ||||||
| Warfarin, 1 mg/d | 34/471 (7.2) | 7/471 (1.5) | ||||||||
| 41 | Acenocoumarine, 1 mg/d | 24/114 (21.1) | P < .01 (vs control) | 1/114 (0.9) | P = .57 | 0/114 | NR | |||
| Dalteparin, 5000 U/d | 48/120 (37.5) | P = .05 (vs control) | 3/120 (2.5) | 0/120 | ||||||
| Control | 57/114 (50) | 3/114 (2.6) | 0/114 | |||||||
| 42 | Warfarin, 1 mg/d | 8/134 (6) | RR: 0.55 (95% CI: 0.31-0.96), P = .0357 (comparison of warfarin/LMWH vs control) | 0/134 | NR | 0/134 | NR | |||
| Prophylactic dose LMWH | 14/138 (10) | 3/138 (2.2) | 0/138 | |||||||
| Control | 20/135 (14) | 9/135 (6.7) 1 fatal PE | 0/135 | |||||||
| Reference . | Intervention . | Thrombosis, n/N (%) . | P . | Symptomatic thrombosis, n/N (%) . | P . | Major bleeding, n/N (%) . | P . | Clinically relevant nonmajor bleeding, n/N (%) . | P . | |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 | Control | 15/40 (37.5) | P < .001 | 13/40 (32.5) | NR | |||||
| Warfarin, 1 mg/d | 4/42 (9.5) | 4/42 (9.5) | ||||||||
| 31 | Control | 8/13 (62) | P = .002 | NR | NR | 0/13 | NR | |||
| Dalteparin, 2500 U/d | 1/16 (6) | 1/16 (6) | ||||||||
| 32 | Control | 15/115 (13) | P = .03 | 0/115 | NR | |||||
| Warfarin, 1 mg/d | 5/108 (5) | 0/108 | ||||||||
| 33 | Control | 3/29 (10.3) | NR | 0/29 | NR | |||||
| Warfarin, 1 mg/d | 7/55 (12.8) | 3/55 (5.5) | ||||||||
| 34 | Control | 5/43 (11.6) | P = .42 | 0/43 | NR | |||||
| Warfarin, 1 mg/d | 8/45 (17.8) | 1/45 (2.2) | ||||||||
| 35 | Warfarin, 1 mg/d | 4/24 (16.7) | P = .48 | 2/24 (8.3) | NR | 0/24 | NR | |||
| Nadroparin, 2850 U/d | 6/21 (23.8) | 1/21 (4.8) | 1/21 (4.8) | |||||||
| 36 | Enoxaparin, 40 mg/d | 22/155 (12.9) | RR: 0.78 (95% CI: 0.47-1.31; P = .35) | 2/155 (1.3) | RR: 0.32 (95% CI: 0.07-1.66) | 0/155 | NR | |||
| Placebo | 28/155 (14.2) | 6/155 (3.9) | 0/155 | |||||||
| 37 | Warfarin, 1 mg/d | 6/130 (4.6) | HR: 1.20; (95% CI: 0.37-3.94) | 0/130 | P = .07 | |||||
| Placebo | 5/125 (4) | 3/125 (2.4) | ||||||||
| 38 | Dalteparin, 5000 U/d | 21/294 (7.1) | NR | 11/294 (3.7) | OR: 1.09 (95% CI: 0.37-3.19) P = .88 | 1/294 (0.3) | NR | |||
| Placebo | 11/145 (7.6) | 5/145 (3.4) | 1/145 (0.7) | |||||||
| 39 | Nadroparin, 2850 U | 7/41 (17) | P = .49 | 0/41 | NR | 0/56 | NR | 2/56 (4) | NR | |
| Placebo | 4/46 (9) | 1/46 (2.2) | 0/57 | 2/57 (4) | ||||||
| 40 | Warfarin, 1 mg/d | 24/408 (5.9) | RR: 0.99 (95% CI: 0.57-1.72), P = .98 | 7/408 (1.7) | RR: 6.93 (95% CI: 0.86-56.08), P = .07 | |||||
| No warfarin | 24/404 (5.9) | 1/404 (0.25) | ||||||||
| Warfarin (INR 1.5-2.0) | 13/473 (2.7) | RR: 0.38 (95% CI: 0.20-0.71), P = .002 | 16/473 (3.4) | RR: 2.28 (95% CI: 0.95-5.48), P = .09 | ||||||
| Warfarin, 1 mg/d | 34/471 (7.2) | 7/471 (1.5) | ||||||||
| 41 | Acenocoumarine, 1 mg/d | 24/114 (21.1) | P < .01 (vs control) | 1/114 (0.9) | P = .57 | 0/114 | NR | |||
| Dalteparin, 5000 U/d | 48/120 (37.5) | P = .05 (vs control) | 3/120 (2.5) | 0/120 | ||||||
| Control | 57/114 (50) | 3/114 (2.6) | 0/114 | |||||||
| 42 | Warfarin, 1 mg/d | 8/134 (6) | RR: 0.55 (95% CI: 0.31-0.96), P = .0357 (comparison of warfarin/LMWH vs control) | 0/134 | NR | 0/134 | NR | |||
| Prophylactic dose LMWH | 14/138 (10) | 3/138 (2.2) | 0/138 | |||||||
| Control | 20/135 (14) | 9/135 (6.7) 1 fatal PE | 0/135 | |||||||
NR, not reported.